Specific primer for detecting lactobacillus salivarius in complex environment sample and application thereof
By designing specific primer pairs and kits, the problem of Lactobacillus salivary detection in complex environmental samples was solved, and high-precision detection was achieved, supporting its application in the treatment of diarrhea and tumor patients.
Patent Information
- Application Number
- CN202411256044.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-09
- Publication Date
- 2024-11-22
AI Technical Summary
The prior art is difficult to accurately detect the colonization of Lactobacillus salivary in complex environmental samples, especially in the intestine, which affects its application in the treatment of diarrhea and its promotion of clinical applications.
A specific primer pair (SEQ ID NO.1 and SEQ ID NO.2) and kit were designed to detect Lactobacillus salivary Lsali-1, and the content of this strain was quantitatively detected in fecal samples by PCR and qPCR. , providing accurate detection methods.
High-precision Lactobacillus salivary detection in complex environmental samples was achieved, supporting the formulation of personalized treatment plans for patients with diarrhea and tumors caused by chemotherapy, reducing the cost of testing.
Smart Images

Figure CN118995973A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of microbial detection, and relates to a primer pair for detecting Lactobacillus salivarius in complex environmental samples and an application thereof, in particular to the application in preparing a preparation for detecting a subject's tolerance to several diarrheas. Background Art
[0002] In recent years, research related to intestinal microbiota and human health has emerged in an endless stream, and has become a hot topic in microbial research. Probiotics are active beneficial microorganisms that colonize in the human and animal intestines and reproductive systems, and can produce definite health effects, thereby improving the host's microecological balance and playing a beneficial role. Colonization is a prerequisite for probiotics to function in the body, so understanding the colonization of probiotics in the body can assist in evaluating their effectiveness and help guide medication. qPCR technology can be used to determine the number of bacterial species in a sample.
[0003] At present, the common methods for detecting the colonization ability of strains are as follows: A. Fluorescence imaging: by feeding strains labeled with fluorescent proteins, the location and number of the target strain in the intestine are detected; B. Metagenomic sequencing: by metagenomic sequencing, the relative abundance of the target strain is detected; C. Live bacteria count: by using selective culture medium to count the live bacteria of the target strain; D. qPCR detection: using universal primers to quantitatively detect strains at the phylum / family / genus / species level. qPCR detects the colonization ability of strains, and generally uses universal primers to detect the strain content at the phylum / family / genus / species level. It is difficult to design specific primers, and in the context of complex bacterial flora, there are technical challenges in tracking individual strains, making it difficult to achieve accurate quantification of strains.
[0004] There are no reports on the clinical application of intestinal probiotics (especially Lactobacillus salivarius) to treat anti-tumor therapy-related diarrhea. If such probiotics can be prepared, it may reduce side effects during treatment, and the cost of culturing microorganisms is low. Of course, detecting whether there are such active bacteria in the intestinal flora of the subjects is also helpful to evaluate the subjects' own ability to resist tumor therapy-related diarrhea or related symptoms, and help guide personalized treatment plans for tumor patients. Summary of the invention
[0005] The purpose of the present invention is to provide a specific primer for detecting Lactobacillus salivarius Lsali-1 in complex environmental samples such as feces and its application, so as to solve the problems of colonization detection and strain identification faced in animal efficacy experiments or clinical practice.
[0006] More specifically, in order to solve the problems existing in the prior art, the first aspect of the present invention provides a specific primer pair, the sequences of the primer pair are shown as SEQ ID NO.1 and SEQ ID NO.2 respectively.
[0007] The second aspect of the present invention provides a kit, which contains the primer pair described in the first aspect of the present invention.
[0008] The third aspect of the present invention provides a method for detecting Lactobacillus salivarius with a microorganism deposit number of CCTCC NO: M2023348 for non-diagnostic purposes, the method comprising: using the primer pair described in the first aspect of the present invention, or the kit described in the second aspect of the present invention, to detect the genomic template in the sample to be tested.
[0009] One application scenario of the method for detecting Lactobacillus salivarius with a microbial preservation number of CCTCC NO: M2023348 for non-diagnostic purposes is: in order to study the competitive advantage of Lsali-1 over other bacteria, the two are mixed and cultured, and then the absolute or relative content of Lsali-1 in the culture is detected, so as to know the competitive advantage of the two bacteria in the common ecological environment and understand the competition mechanism of the two bacteria.
[0010] In some embodiments, the microorganisms contained in the sample to be detected are determined by detecting the electrophoresis image of the amplified product by the PCR method; or
[0011] The microorganisms contained in the sample to be detected are determined by the qPCR method.
[0012] The fourth aspect of the present invention provides a use, which is: use of the aforementioned specific primer pair or the aforementioned kit in preparing a preparation for evaluating the therapeutic effect of probiotics, wherein the probiotics are Lactobacillus salivarius with a microbial preservation number of CCTCC NO: M2023348.
[0013] In some embodiments, the therapeutic effect is the effect of treating diarrhea caused by chemotherapy drugs or diarrhea caused by any one or more of Pseudomonas aeruginosa, Shigella, Escherichia coli, Salmonella paratyphi B, Yersinia enterocolitica, Staphylococcus aureus, Vibrio parahaemolyticus, and Clostridium difficile.
[0014] Lsali-1 is derived from human volunteer feces, is safe and has no toxic factors and has the purpose of improving health. When Lsali-1 is used as a probiotic to regulate human health, the actual or approximate action state of Lsali-1 can be evaluated by at least detecting the absolute or relative content of Lsali-1 in the intestinal contents or feces after administration of Lsali-1 through the primer pair or the kit. Therefore, this use is based on the actual contribution of the present invention.
[0015] The fifth aspect of the present invention provides a use, which is: use of the aforementioned specific primer pair or the aforementioned kit in the preparation of a preparation for formulating or adjusting a treatment plan for tumor patients.
[0016] Lsali-1 can reduce diarrhea and damage to the intestine caused by chemotherapy drugs (e.g., 5-fluorouracil). Therefore, for patients with or without Lsali-1 in the intestine, it is possible to consider appropriately reducing or increasing the type or dose of anticancer drugs. By using the primer pair described in the first aspect of the present invention and the kit described in the second aspect of the present invention, Lsali-1 in intestinal contents or feces can be detected, and reference data can be provided for tumor patients to formulate or adjust treatment plans. Therefore, this use is also based on the actual contribution of the present invention.
[0017] The method for realizing the fourth or fifth use is: qualitatively or quantitatively detecting Lactobacillus salivarius with a microbial preservation number of CCTCC NO: M2023348 in the intestinal contents or feces of the subject.
[0018] In the aforementioned use, the chemotherapy drug is selected from 5-fluorouracil, capecitabine, gemcitabine, methotrexate, pemetrexed, cytarabine, doxorubicin, epirubicin, dactinomycin D, doxorubicin, daunorubicin, paclitaxel, docetaxel, albumin paclitaxel, cisplatin, carboplatin, nedaplatin, oxaliplatin, lobaplatin, cyclophosphamide, nitrogen mustard, carmustine, camptothecin, hydroxycamptothecin, topotecan, irinotecan and their derivatives.
[0019] The effects of the present invention are: 1. A specific primer for Lactobacillus salivarius CCTCCNO:M2023348 is screened and obtained; 2. The specific primer can have a higher accuracy in complex environmental samples. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] Figure 1 This is a front view photo of the colony morphology of Lactobacillus salivarius Lsali-1.
[0021] Figure 2 These are the results of the in vitro total antioxidant test of Lactobacillus salivarius Lsali-1 and Lactobacillus rhamnosus GG.
[0022] Figure 3 These are the results of the antibacterial test of Lactobacillus salivarius Lsali-1 against a variety of pathogenic bacteria.
[0023] Figure 4 These are the results of the in vitro cell inflammation inhibition test of each experimental group. A is the result of the effect on IL-6 expression, and B is the result of the effect on TNF-α expression.
[0024] Figure 5These are the experimental results of Lactobacillus salivarius Lsali-1 on intestinal barrier repair.
[0025] Figure 6 Figure 2 is the therapeutic effect of each experimental group on mice with diarrhea caused by 5-fluorouracil. A shows the diarrhea score curves of each group from day 1 to day 9; B shows the total diarrhea score of each group.
[0026] Figure 7 Figure 1 is the therapeutic effect of Lactobacillus salivarius Lsali-1 on mice with radiation enteritis. A is the diarrhea score curve of each group from day 1 to day 9, B is the D5 diarrhea score of each group, C is the total diarrhea score of each group, and D is the hemoglobin content.
[0027] Figure 8 It is the result of the initial screening specific primer detection.
[0028] Fig. 9 It is the result of repeated screening of specific primers.
[0029] Fig.10 It is the PCR test result.
[0030] Fig.11 This is the result of qPCR detection of Lactobacillus salivarius Lsali-1 in feces. DETAILED DESCRIPTION
[0031] In order to make the objectives, technical solutions and advantages of the present invention clearer, the embodiments of the present invention will be further described in detail below in conjunction with the accompanying drawings, and the contents of patent CN202410604978.2 are incorporated into this application for reference.
[0032] Preparation of triple-mixed liquid culture medium (BHI+MRS+modified GAM): weigh 19.25 g of BHI broth powder (Qingdao Haibo Biotechnology Co., Ltd., HB8297-5), 13.5 g of MRS broth powder (Guangdong Huankai Biotechnology Co., Ltd., 027312), and 15 g of modified GAM broth powder (Qingdao Haibo Biotechnology Co., Ltd., HB8518-3), dissolve in 1 L of distilled water, deoxygenate with N2 replacement and package, sterilize at 121°C for 30 min, and store in a cool and dry place.
[0033] Preparation of BF839 medium: weigh 6.0 g potato extract powder (Beijing Solebow Technology Co., Ltd., FA0270), 10.0 g polyvalent peptone (Beijing Solebow Technology Co., Ltd., P8950-250), Peptone (HB8277, Qingdao Hi-Tech Industrial Park Haibo Biotechnology Co., Ltd.), sodium thioglycolate (Shanghai Aladdin Biochemical Technology Co., Ltd., S105664-25G), yeast extract powder (Thermo Fisher Oxoid, LP0021B), glucose (50-99-7, Chengdu Kelong Chemical Co., Ltd.), sodium dihydrogen phosphate (7558-79-4, Chengdu Kelong Chemical Co., Ltd.), 4.0 g were dissolved in 1 L of distilled water, deoxygenated by N2 replacement, and packaged separately. Sterilize at 121 °C for 30 min and store in a cool and dry place.
[0034] Preparation of the second mixed culture medium (BHI+MRS): Weigh 19.25 g of BHI broth powder, 27.0 g of MRS broth powder, and 0.5 g of cysteine hydrochloride monohydrate (Longteng Biotechnology Co., Ltd.), dissolve in 1 L of distilled water, deoxygenate and package, sterilize at 121°C for 15 min, and store in a cool and dry place.
[0035] MRS solid medium, GAM solid medium, TSB (Tryptone Soy Broth, Qingdao Haibo Biotechnology Co., Ltd., HB4114), and TSA (Tryptone Soy Agar, Qingdao Haibo Biotechnology Co., Ltd., HB4138) medium were prepared according to the instructions, weighed and dissolved, sterilized at 121°C for 30 min, and stored in a cool and dry place.
[0036] Preparation of culture medium for bacterial powder: weigh 24g of anhydrous glucose, 20g of soy peptone, 10g of yeast extract powder, 10g of peptone, 5g of sodium acetate, 2g of potassium dihydrogen phosphate, 2g of disodium hydrogen phosphate, 0.1g of magnesium sulfate, 0.045g of manganese sulfate, 1ml of Tween 80, and 0.5g of monohydrated cysteine hydrochloride, and dissolve them in 1L of purified water. Deoxygenate by N2 replacement, aliquot, sterilize at 121℃ for 15min, and store in a cool and dry place.
[0037] Example 1: Isolation and identification of new strains
[0038] Fresh fecal samples from healthy human volunteers were collected, and monoclonal strains were obtained after resuspending, filtering, centrifuging, separating, culturing, and transferring. The PCR results of the strains were sequenced and analyzed, and the sequences were compared with the NCBI nt library. The results showed that the sequence similarity with a strain of Lactobacillus salivarius was the highest (100.00%). Therefore, they were preliminarily identified as Lactobacillus salivarius, also known as salivary Lactobacillus (Latin name Ligilactobacillus salivarius), and named Lactobacillus salivarius Lsali-1 (abbreviated as Lsali-1). Its colony morphology is white opaque round colonies with a convex middle and a smooth and moist surface. The front photo is shown in Figure 1 .
[0039] Example 2: Whole genome analysis and identification of new strains
[0040] The strain Lsali-1 was inoculated into a three-mixed liquid medium and cultured to the late logarithmic growth stage. The whole genome DNA of the strain was extracted and the whole genome was sequenced using the Illumina high-throughput sequencing platform NovaSeq 6000. After assembly and annotation, the protein sequence was entered into the Virulence Factor Databases (VFDB) for virulence factor analysis. The results showed that the bacteria did not have virulence factors. By searching in Genbank, 215 published Lactobacillus salivarius whole genomes were found. By comparing with fastANI (v1.33), it was found that the two strains most similar to the whole genome of Lactobacillus salivarius Lsali-1 were GCA_009863605.1 (ANI=99.94%) and GCA_009866185.1 (ANI=99.87%), so Lactobacillus salivarius Lsali-1 can be considered as a new strain.
[0041] The strain Lsali-1 was deposited in the China Center for Type Culture Collection (CCTCC) on March 17, 2023. The center’s address is Wuhan University, Wuhan, China. The strain’s deposit number is CCTCCNO: M2023348, the culture name is: Lactobacillus salivarius Lsali-1, the Chinese classification name is: Lactobacillus salivarius, the English classification name is: Lactobacillus salivarius, and the identification survival date is: March 24, 2023.
[0042] Example 3: Hemolysis test of Lactobacillus salivarius Lsali-1
[0043] Lactobacillus salivarius Lsali-1 was inoculated into a three-mixed liquid medium and cultured anaerobically at 37°C until the late logarithmic growth period to obtain an activated strain. 2 mL of 2% fresh rabbit red blood cell suspension (Beijing Borsi Technology Co., Ltd.) and 2 mL of 0.9% sterile saline (Shandong Qidu Pharmaceutical Co., Ltd.) were resuspended and the bacterial suspension was tested by liquid contact method, with an equal volume of sterile water as a positive control (hemoglobin is released after red blood cells absorb water and burst), and an equal volume of 0.9% sterile saline as a negative control. Three parallels were set for each group, and each sample was photographed after standing for 24 hours. The results showed that the Lactobacillus salivarius Lsali-1 bacterial suspension had no hemolysis, so there was no risk of hemolysis when applied to the human body.
[0044] Example 4: Antioxidant Experiment of Lactobacillus salivarius
[0045] The preserved Lactobacillus salivarius Lsali-1 was activated and inoculated into 5 mL BF839 medium at a 2% inoculum size. Lactobacillus rhamnosus GG (CICC6141, China Industrial Microbiological Culture Collection Center, abbreviated as LGG) was used as a positive control. All strains were anaerobically cultured in BF839 medium at 37°C for 24 h.
[0046] Sample processing: Take 0.5mL of culture solution and centrifuge at 12000rpm for 20min, discard the supernatant, and resuspend with 0.5mL of the extract (pre-cooled) in the strain total antioxidant capacity detection kit (the kit was purchased from Beijing Solebow Technology Co., Ltd., BC1315); transfer to a sterile screw-cap tube containing beads (Sigma, USA, G4649-1KG), oscillate and break the wall once with a rapid sample preparation instrument (parameter setting: 4.5m / s, 30s), then centrifuge at 12000rpm and 4℃ for 10min, and take the supernatant and place it on ice for testing.
[0047] A BCA protein concentration determination kit (the kit was purchased from Beijing Solebow Technology Co., Ltd., PC0020) was used to draw a standard curve and detect BCA samples according to the instructions of the kit.
[0048] The total antioxidant capacity detection kit of strains was used to determine the antioxidant capacity of the samples according to the instructions of the kit and the standard curve. The total antioxidant capacity unit is μmol / mg prot.
[0049] The experimental results can be found in Figure 2 .Depend on Figure 2 It can be seen that the total antioxidant capacity of Lactobacillus salivarius Lsali-1 reached 0.398 μmol / mgprot, which was significantly higher than that of the positive control strain Lactobacillus rhamnosus GG (p<0.05), indicating that Lactobacillus salivarius Lsali-1 has strong antioxidant capacity in vitro.
[0050] Example 5: Test of the antibacterial ability of Lactobacillus salivarius against pathogenic bacteria
[0051] Eight common pathogens that cause diarrhea were selected for antibacterial ability testing. The source information of the pathogenic strains is as follows: Pseudomonas aeruginosa (CMCC(B)10104), purchased from China Food and Drug Inspection Institutes. Shigella (CMCC(B)51252), purchased from China Food and Drug Inspection Institutes. Escherichia coli (CMCC(B)44102), purchased from China Food and Drug Inspection Institutes. Salmonella paratyphi B (CMCC(B)50094), purchased from China Food and Drug Inspection Institutes. Staphylococcus aureus (CMCC(B)26003), purchased from China Food and Drug Inspection Institutes. Yersinia enterocolitica CMCC(B)52204, purchased from China Food and Drug Inspection Institutes. Vibrio parahaemolyticus (ATCC 17802), purchased from the American Microbiological Collection. Clostridium difficile (CICC 22951) was purchased from China Industrial Microbiological Culture Collection Center. Preparation of Lactobacillus salivarius Lsali-1 fermentation broth: After activation, Lactobacillus salivarius Lsali-1 was inoculated into a three-mixed liquid culture medium and anaerobically cultured at 37° C. for 48 hours to obtain a fermentation broth.
[0052] Preparation and coating of pathogens: Pseudomonas aeruginosa, Shigella, Escherichia coli, Salmonella paratyphi B, Yersinia enterocolitica, Staphylococcus aureus and Vibrio parahaemolyticus are aerobic bacteria. After activation with TSB broth medium, they were diluted 50 times in TSB broth medium to reach the appropriate concentration, and 0.2 mL of the diluted bacterial solution was coated on TSA solid medium. Clostridium difficile is an anaerobic bacterium. After activation and transfer, it was diluted 50 times in a three-mixed liquid medium, and 0.2 mL of the diluted Clostridium difficile bacterial solution was coated on sterile anaerobic GAM solid medium (added with 5% horse serum, Beijing Solebow Technology Co., Ltd., S9050).
[0053] Co-cultivation of Lactobacillus salivarius Lsali-1 and pathogens: Place 3 sterilized Oxford cups on the coated pathogen plate, add 0.2 mL of Lactobacillus salivarius Lsali-1 fermentation liquid into the Oxford cups, place in an anaerobic culture box (anaerobic pathogens plus anaerobic gas production bag), place the plate upright for 24 hours, and measure the size of the inhibition zone with a vernier caliper.
[0054] The results are as follows Figure 3 As shown: Lactobacillus salivarius Lsali-1 has antibacterial ability against Pseudomonas aeruginosa, Shigella, Salmonella paratyphi B, Yersinia enterocolitica, Staphylococcus aureus, Vibrio parahaemolyticus and Clostridium difficile.
[0055] Example 6: In vitro cell inflammation inhibition test of Lactobacillus salivarius
[0056] THP-1 cell polarization: THP-1 (Shangcheng Beina Chuanglian Biotechnology Co., Ltd., BNCC No. 358410) is a suspension cell, and PMA (phorbol 12-myristate 13-acetate, purchased from Sigma-Aldrich Company, P1585) is used to induce THP-1 to polarize into mature macrophages. On this basis, LPS (purchased from Sigma-Aldrich Company, L3024) and IFN-γ were further used to induce mature macrophages to polarize into inflammatory macrophages. RPMI-1640 (purchased from Thermo Fisher Scientific (China) Co., Ltd., C11875500BT) medium containing 10% FBS and a final concentration of 100 ng / mL PMA was used, and 1×10 5 THP-1 cells were seeded in a 96-well plate at a seeding density of 10 cells / well, placed in a 5% CO2 incubator, and cultured at 37°C for 24 h. The medium was then replaced with RPMI-1640 medium containing 10% FBS, a final concentration of 100 ng / mL LPS, and 20 ng / mL IFN-γ, and placed in a 5% CO2 incubator and cultured at 37°C for 24 h.
[0057] Strain culture: Take 200 μL of Lactobacillus salivarius Lsali-1 bacterial solution from the bacterial storage and add it to 5 mL of the second mixed culture medium (the relevant reagents are deoxygenated in advance), and culture it anaerobically in a 37°C electric constant temperature incubator for 24 hours. After transferring once, culture it anaerobically for 8 hours. Take 1 mL of the bacterial solution, centrifuge it at 5000 rpm / min for 15 minutes. Dilute the strain to 5×10 with RPMI-1640 medium containing 10% FBS. 7 CFU / mL is reserved.
[0058] Effect of Lactobacillus salivarius Lsali-1 on the expression of TNF-α and IL-6 in THP-1 cells: After PMA polarization, mature macrophages were deprived of culture medium and 100 μL of RPMI-1640 culture medium containing 10% FBS was added as the normal control group; the inflammatory macrophages were further induced, the culture medium was deprived of culture medium, and 100 μL of RPMI-1640 culture medium containing 10% FBS was added as the model group; the positive control group was added with 100 μL of RPMI-1640 culture medium containing 10% FBS and dexamethasone (purchased from Sigma-Aldrich Company, D4902-25) at a final concentration of 25 μg / mL; the experimental group was added with 100 μL of Lactobacillus salivarius Lsali-1 culture liquid prepared in advance. Place in a 5% CO2 incubator and culture at 37°C for 24 hours. 80 μL of cell culture medium was aspirated, centrifuged at 4°C, 5000 rpm / min for 15 min, and the supernatant was collected. The TNF-α content was detected using a Human TNF-α (Tumor Necrosis Factor Alpha) ELISA kit (purchased from Wuhan Elaruite Biotechnology Co., Ltd., E-EL-H0109c), and the IL-6 content was detected using a Human IL-6 (Interleukin 6) ELISA kit (purchased from Wuhan Elaruite Biotechnology Co., Ltd., E-EL-H6156).
[0059] Experimental results: Figure 4 As shown in the figure, the expression of TNF-α and IL-6 in the inflammatory model group was significantly higher than that in the normal control group; the positive control dexamethasone and Lactobacillus salivarius Lsali-1 could significantly inhibit the expression of pro-inflammatory factor IL-6 in THP-1 cells. Figure 4 A) and TNF-α ( Figure 4 B) expression, indicating that Lactobacillus salivarius Lsali-1 has a very significant anti-inflammatory effect in vitro.
[0060] Example 7: In vitro barrier repair test of Lactobacillus salivarius Lsali-1
[0061] Caco-2 cells (BNCC Biotechnology Co., Ltd., BNCC No.: 350769) were seeded into Transwell (permeable cell culture chamber): Caco-2 is an adherent cell and needs to be digested with trypsin cell digestion solution preheated at 37°C. DMEM medium containing 10% FBS and 1% PS (DMEM medium, purchased from Gibco, catalog number C11995500BT; FBS, purchased from Gibco, catalog number 16000-044; PS, penicillin-streptomycin mixture, purchased from Gibco, catalog number 15140-122) was used at 1.1×10 5 Caco-2 cells were seeded in a 24-well Transwell at a seeding density of 10 cells / well and cultured statically at 37°C with 5% CO2 for 21 days.
[0062] Strain culture: Take 200 μL of Lactobacillus salivarius Lsali-1 bacterial solution from the bacterial storage and add it to 5 mL of the second mixed culture medium (the relevant reagents are deoxygenated in advance), and culture it anaerobically in a 37°C electric constant temperature incubator for 24 hours. Subculture once and culture it anaerobically for 8 hours. Take 1 mL of the bacterial solution and centrifuge it at 12000 rpm / min for 3 minutes. Dilute the strain to 10 with DMEM medium containing 10% FBS. 7 CFU / mL, set aside. Use the same concentration of Lactobacillus rhamnosus GG as a positive control.
[0063] Effect of Lactobacillus salivarius Lsali-1 on intestinal epithelial barrier function in Caco-2 cell model: This experiment was divided into 4 groups, namely normal control group, barrier injury group (model group), positive control group, and Lactobacillus salivarius Lsali-1 group. The inflammatory factors IFN-γ (Pepro Tech, AF-300-02) and TNF-α (Pepro Tech, 300-01A) were used to construct a barrier injury model as the model group. After Caco-2 cells were cultured for 21 days, they differentiated into dense monolayer cells, the old culture medium in the lower chamber was removed, 800 μL of DMEM culture medium was added to the lower chamber of the normal control group, and 800 μL of IFN-γ solution with a concentration of 10 ng / mL was added to the lower chamber of the model group, positive control group, and Lactobacillus salivarius Lsali-1 group. The cells were placed in a 5% carbon dioxide incubator and cultured at 37°C for 22 hours. The upper and lower chamber solutions were removed. 200 μL DMEM medium was added to the upper chamber of the normal control group and 800 μL DMEM medium was added to the lower chamber. 200 μL DMEM medium was added to the upper chamber of the model group. 200 μL positive bacterial solution was added to the upper chamber of the positive control group. 200 μL Lactobacillus salivarius Lsali-1 bacterial solution was added to the upper chamber of the Lactobacillus salivarius Lsali-1 group. 800 μL TNF-α solution with a concentration of 50 ng / mL was added to the lower chamber of the model group, the positive control group and the Lactobacillus salivarius Lsali-1 group. The cells were placed in a 5% carbon dioxide incubator and cultured at 37°C for 5 hours. The cell monolayer transmembrane electrical resistance (TEER) values of each group were detected.
[0064] The results are as follows Figure 5 As shown: Compared with the barrier damage group, LGG and Lactobacillus salivarius Lsali-1 can significantly increase the TEER value and have a significant repair effect on cell barrier damage. The results show that Lactobacillus salivarius Lsali-1 can effectively alleviate the barrier dysfunction caused by inflammatory factors (such as IFN-γ, TNF-α).
[0065] Example 8: Therapeutic effect of Lactobacillus salivarius on 5-FU-induced diarrhea in mice
[0066] Lyophilization protective agent preparation:
[0067] Liquid A: 8g sucrose, 8g trehalose, 44g purified water, sterilized at 115℃ for 30min; Liquid B: 2g sodium glutamate, 2g arginine hydrochloride, 16g purified water, sterilized at 115℃ for 30min.
[0068] Solution C: 4g of sodium vitamin C, 16g of purified water, filter and sterilize for later use.
[0069] When using, mix in a volume ratio of A:B:C=6:2:2.
[0070] Preparation of bacterial powder: Lactobacillus salivarius Lsali-1 and another control strain of the same species, Lactobacillus salivarius Lsali-4 (same species isolated by similar methods) were inoculated into bacterial powder preparation medium, and cultured at 37°C to obtain a primary seed solution (OD 600 Then, the inoculation amount was transferred to the bacterial powder to prepare the culture medium at 1.5%, and the culture was statically cultured at 37°C for 6-8 hours to obtain the secondary seed solution (OD 600 The secondary seed solution was pumped into the fermentation tank with a peristaltic pump at a 1.5% inoculation rate, and the fermentation parameters (37°C, pH 6.0, 100 rpm, 0.06 MPa) were set for fermentation. 600 Value ≥2.0 or OD 600 When the value increases by ≤0.1, stop fermentation, set the fermentation temperature to 20℃, and collect the bacteria by centrifugation. Add lyophilization protective agent at a weight ratio of 1:1 to 1:2 to mix the emulsified sludge. Place the emulsified bacterial suspension on the plate layer of a freeze dryer precooled to -40℃ for freeze drying. After the freeze drying process is completed, take out the bacterial cake and crush it to obtain bacterial powder. Before animal administration, use 0.2mL of normal saline to mix 1×10 9 CFU bacterial powder was prepared into bacterial suspension.
[0071] Experimental animals: SPF male Balb / c mice, weighing 18-22 g, were purchased from Beijing Weitonglihua Experimental Animal Technology Co., Ltd. and kept in an SPF animal room. The mice were randomly divided into 4 groups according to their initial weight, with 5 mice in each group.
[0072] Experimental design: A 5-FU (5-fluorouracil, purchased from Tianjin Jinyao Pharmaceutical Co., Ltd., specification 10mL / tube, 0.25g / 10mL) solution was used to induce a mouse chemotherapy-related diarrhea model. The four experimental groups were normal control group, model control group, Lactobacillus salivarius Lsali-1 group and Lactobacillus salivarius Lsali-4 group. The overall experimental period was 9 days, recorded as D1-D9. D1-D5 were administered by gavage for 5 consecutive days, and a single modeling treatment was performed on D3. Except for the normal control group, which was intraperitoneally injected with normal saline, other groups were treated with a single intraperitoneal injection of 5-FU for modeling, and the modeling dose was 350mg / kg (body weight). All groups were administered by gavage. The normal control group and the model control group were gavaged with freeze-dried protective agent; the Lactobacillus salivarius Lsali-1 group and the Lsali-4 group were gavaged with 1×10 9 After the administration of D5, the mice were observed for 4 consecutive days. The specific experimental groups and administration schemes are shown in Table 1.
[0073] Table 1. Trial groups and dosing regimens
[0074]
[0075] Note: 5-FU: 5-fluorouracil; CFU: colony forming unit; d: day
[0076] Diarrhea observation and scoring: Place mice in a mouse cage lined with clean filter paper, 1 in each cage. Hard stools and normal stools are scored as 0 points; mild, slightly wet stools or soft stools are scored as 1 point; moderate, wet stools, unformed stools and unclean perianal area are scored as 2 points; severe, loose stools and severe unclean perianal area are scored as 3 points. During the experimental period, the feces of mice were observed and scored every day. The total diarrhea score is the sum of the daily diarrhea scores. The test results are as follows: Figure 6 As shown in the figure, compared with the model control group, the Lsali-1 administration group had a significant improvement effect on 5-FU-induced diarrhea ( Figure 6 A); the total diarrhea score of Lsali-1 was significantly lower than that of the model control group (P<0.05), and its improvement effect was better than that of the control strain Lsali-4 ( Figure 6 B).
[0077] In summary, Lsali-1 has a significant therapeutic effect on 5-FU-induced diarrhea in mice.
[0078] Example 9: Therapeutic effect of Lactobacillus salivarius Lsali-1 on mice with radiation enteritis
[0079] Experimental design: 28 male C57BL / 6 mice were purchased from Chengdu Yaokang Biotechnology Co., Ltd. and kept in an SPF animal room. According to body weight, they were randomly divided into a normal control group (materials and doses: lyophilized protective agent, the same as in Example 8, 200 μL / mouse), a model control group (materials and doses: lyophilized protective agent, 200 μL / mouse), a loperamide group (purchased from Xi'an Janssen Pharmaceutical Co., Ltd., dose: 15 mg / kg body weight; 10 ml / kg body weight), a standard strain of Lactobacillus salivarius DSM20555 (purchased from the German Collection of Microorganisms and Cell Cultures, dose: 1×10 9 CFU / mouse / day; 200 μL / mouse) group and Lsali-1 (dose: 1×10 9 CFU / mouse / day; 200μL / mouse) groups, 5-6 mice in each group, a total of 5 groups. Except for the normal control group, the mice in the other groups were subjected to a single full abdominal X-ray irradiation with an irradiation dose of 11.5Gy, and the day of irradiation was defined as D0. The overall experimental period was from D-2 to D10, a total of 13 days. Each group was gavaged and administered once a day for 12 consecutive days. The experimental grouping and dosing regimen are shown in Table 2.
[0080] Table 2. Experimental groups and dosing regimens for the treatment of radiation enteritis in mice
[0081]
[0082] During the experiment, general health observations were conducted every day, including but not limited to the animals' physical signs, behavioral activities, respiration, glandular secretions, feces, etc. The diarrhea of each animal after irradiation modeling was observed and recorded, and scored. After administration on D9, the animals were fasted but not watered overnight, and peripheral blood was collected on D10 to test the hemoglobin content.
[0083] Diarrhea score: Mice were placed in a mouse cage lined with clean filter paper, with one mouse in each cage. Hard stools and normal stools were scored as 0 points; mild, slightly wet stools or soft stools were scored as 1 point; moderate, wet stools, unformed stools and unclean perianal area were scored as 2 points; severe, loose stools and severe unclean perianal area were scored as 3 points. The total diarrhea score was the sum of the diarrhea scores for each day.
[0084] Hemoglobin content detection: Whole blood samples were collected from each group of animals through the vein for hemoglobin content (HGB) detection (veterinary automatic blood cell analyzer, model: BC-2800Vet; Shenzhen Mindray Bio-Medical Electronics Co., Ltd.).
[0085] The experimental results are expressed as Mean±SEM, and one-way ANOVA was used for multiple comparison analysis. * indicates p<0.05 compared with the model control group, ** indicates p<0.01 compared with the model control group, and **** indicates p<0.0001 compared with the model control group.
[0086] Test results: Figure 7 As shown, loperamide and Lasli-1 significantly reduced the D5 diarrhea score and D9 total diarrhea score of the model mice ( Figure 7 B, C), significantly improved the decline of HGB in model mice ( Figure 7 D).
[0087] These results suggest that Lasli-1 can significantly improve diarrhea and anemia in mice with radiation enteritis.
[0088] Example 10: Specific primer design and synthesis
[0089] According to the whole genome analysis results of Lactobacillus salivarius Lsali-1, specific genome fragments based on this strain were found, specific primers were designed using Primer Premier 5, and Beijing Qingke Biotechnology Co., Ltd. was commissioned to synthesize primers. The information of the three pairs of primers and the universal primer is detailed in Table 3.
[0090] Table 3. Primer information
[0091]
[0092] The specific fragment screening method is as follows: 1) First, the original genome data is subjected to routine quality control, assembly, and annotation to obtain the gene sequence as the input file. 2) The sequence in the input file is compared with the NCBI nt library by default to check whether these sequences match the data in the database. If a certain sequence has no match in the database, it means that the fragment has strong specificity, which is used as the result.
[0093] Example 11: Single bacteria culture, single bacteria whole genome DNA extraction and feces genomic DNA extraction
[0094] 1) Strain culture: used for whole genome DNA extraction.
[0095] The preserved Lactobacillus salivarius Lsali-1 was activated in a 2% (v / v) inoculum into a three-mixed liquid culture medium and cultured anaerobically at 37° C. to the late logarithmic growth stage.
[0096] 2) A bacterial culture DNA extraction kit (Shanghai Sangon Biotech Co., Ltd., B518255) was used to extract whole genome DNA from the bacterial culture according to the instructions of the kit for specific primer screening.
[0097] 3) A stool DNA extraction kit (Tiangen Biochemical Technology (Beijing) Co., Ltd., DP328-02) was used according to the instructions of the kit to extract stool genomic DNA for specific primer screening.
[0098] Example 12: Screening for specific primers for detecting Lactobacillus salivarius Lsali-1
[0099] In order to screen primers that can specifically amplify the target strain in feces, PCR was used to amplify normal mouse feces. Due to individual differences in mice and differences in intestinal flora composition, 10 normal mouse feces samples were selected to specifically screen the designed primers to enhance reliability. In order to reduce the workload, 2 fecal DNA samples were randomly selected for initial screening of each primer. After no obvious background amplification, 10 fecal DNA samples were used to rescreen each primer and select the primer with the strongest specificity.
[0100] 1) Sample source: extraction of single bacterial whole genome DNA and extraction of 2 or 10 fecal genome DNA in Example 11.
[0101] 2) PCR test:
[0102] ① For primer information, please see Table 3; for primer sequence information, please see Table 4:
[0103] Table 4. Primer sequence information
[0104]
[0105]
[0106] ② PCR amplification system (total system is 25 μl): 1.1×T3 Super PCR Mix (Beijing Qingke Xinye Biotechnology Co., Ltd., TSE030) 22 μl, 10 μmol / L upstream and downstream primers 1 μl each, and template DNA 1 μl, were added into corresponding PCR tubes respectively.
[0107] ③PCR reaction program: Place the constructed reaction system on the PCR instrument and set the corresponding amplification program as follows: 98℃ for 2 min; 98℃ for 10 s, 56℃ for 10 s, 72℃ for 50 s, for a total of 39 cycles; 72℃ for 2 min; store at 4℃.
[0108] 3) Agarose gel electrophoresis results:
[0109] like Figures 8-9 In each gel photo, the primer number is marked on the photo. In the sample number, M: Maker; NC: negative control (normal saline); PC: positive control (genomic DNA of single bacteria Lsali-1); 1-10 (fecal sample number): total DNA extracted from feces. The initial screening results are shown in Figure 8 Primers A and C meet the conditions of no bands in NC, single band in PC, and no bands in fecal DNA samples 1 and 6. The results are verified successfully and used for rescreening. Fig. 9 Primer A met the requirements of no band in NC, single band in PC, and no band in fecal DNA samples 1 to 10, and was successfully verified and used in subsequent experiments; Primer C did not meet the requirements and was excluded.
[0110] Example 13: PCR identification and plasmid construction
[0111] 1) Sequence sequencing identification: The PCR product amplified from the target single bacterial DNA sample corresponding to the primer A that passed the re-screening in Example 12 was entrusted to Beijing Qingke Biotechnology Co., Ltd. for sequencing, and the PCR sequencing result was compared with the whole genome sequencing sequence to confirm that the results were consistent, and then plasmid construction was performed, indicating that the amplification result was in line with expectations.
[0112] 2) Plasmid construction:
[0113] ① According to the primer sequence and the target fragment sequence (the fragment sequence obtained by amplification), Beijing Qingke Biotechnology Co., Ltd. was commissioned to synthesize the plasmid. The target vector was pMD-19T, Amp + Resistance, the amplified fragment was inserted into the target vector to obtain a recombinant plasmid containing the target DNA fragment, and 4 μg of plasmid sample was obtained for each recombinant plasmid.
[0114] ② Take 4 μg of the synthetic plasmid sample (=4000 ng, centrifuge at low speed before use) and add 40 μl of sterile double distilled water to prepare 100 ng / μl plasmid (see Table 5 for plasmid information) and calculate the copy number. The copy number calculation method is as follows:
[0115]
[0116] Table 5. Plasmid and initial screening primer information
[0117]
[0118] 3) PCR identification:
[0119] ① Sample source: Extraction of whole genome DNA of a single bacterium and synthesis of plasmid in Example 11.
[0120] ②PCR detection: Primer information, PCR amplification system, and PCR reaction procedure are the same as those in step 2 of Example 12).
[0121] ③Agarose gel electrophoresis results:
[0122] like Fig.10 As shown in the figure, in each gel photo, the primer number is marked on the photo, and in the sample number, M: Maker; NC: negative control; PC: positive control (synthetic plasmid); 1: single bacterial DNA. The band length of PC (synthetic plasmid) is consistent with that of the sample after amplification, and NC (negative control) has no band, and the plasmid synthesis is successfully verified. After using primer D (universal primer) to amplify the single bacterial DNA, the amplified sample is sequenced by 16S, and the sequencing results are compared to the target strain and the sample is not contaminated.
[0123] Example 14: qPCR detection of specific primers for Lactobacillus salivarius Lsali-1 in mouse feces
[0124] After screening out specific primers, it is necessary to detect the background amplification of the strain-specific primers in mouse feces. If the number of viable bacteria amplified by the background is greater than the animal dosage, the method sensitivity is insufficient and the primers need to be rescreened. Therefore, using the primers (primer A) that passed the rescreening in Example 13, with fecal DNA (negative control), feces + DNA of different concentrations of plasmids (experimental group) and each single bacterial plasmid (positive control group) as templates, the sensitivity of the detection method was finally determined.
[0125] 1) Sample processing:
[0126] ① Sample source: fecal genomic DNA extraction in Example 11.
[0127] ②Sample grouping and mixing: Different concentrations of plasmids were added to the fecal DNA to verify the accuracy of the qPCR method. Each DNA / plasmid sample was grouped and combined according to Table 6 for qPCR detection.
[0128] Table 6. Experimental grouping for method establishment
[0129]
[0130] 2) qPCR detection:
[0131] ②Details of plasmids and primers are shown in Table 5.
[0132] ②qPCR amplification system (total volume is 10 μl): 5 μl of SsoFast Eva Green (Bio-Rad Laboratories (Shanghai) Co., Ltd., 1725201), 2.25 μl of ddH2O, 0.25 μl of BSA (Baori Biotechnology (Beijing) Co., Ltd., 2320), 0.25 μl each of 10 μmol / L upstream and downstream primers, and 2 μl of template DNA were added to the corresponding qPCR tubes respectively.
[0133] ③qPCR reaction program: The constructed reaction system was placed on a qPCR instrument, and the corresponding amplification program was set as follows: 95°C for 2 min; 95°C for 15 s, 56°C for 15 s, 72°C for 10 s, for a total of 45 cycles; 72°C for 5 min; Melt Curve from 65°C to 95°C with an increment of 0.5°C, END.
[0134] ④Standard curve establishment: The plasmid sample was diluted 10-fold according to DNA:ddH2O = 5:45 to dilute the DNA to 10 10 、10 9 、10 8 、10 7 、10 6 、10 5 、10 4 、10 3 、10 2 copies / μl, and placed on ice for standby; loaded and detected according to the qPCR amplification system and qPCR reaction program.
[0135] ⑤Sample detection: The samples in Table 6 were loaded and detected according to the qPCR amplification system and qPCR reaction program.
[0136] Results: The results are as Fig.11 shown in A: R 2 > 0.99, 80% <E <120%, and the standard curve was successfully established. As Fig.11 shown in B: The background value of Lactobacillus salivarius Lsali-1 is relatively low, at 101 ~10 3 The bacterial content of DNA amplification in the experimental group (feces + different concentrations of plasmid) was basically consistent with that in the positive control group (different concentrations of plasmid), indicating that the method was successfully established and the primers can be used to detect the content of Lactobacillus salivarius Lsali-1 in fecal samples.
[0137] It can be seen that the genomic fragment corresponding to primer A is a specific fragment of Lactobacillus salivarius Lsali-1 and can be used to distinguish and identify Lactobacillus salivarius.
[0138] The sequence of the genomic fragment corresponding to primer A is as follows (SEQ ID NO.9):
[0139] GATGAAGACGGTAAGTTAAATCGTAAGACAGTAACATCATTAGTAGTATTGTCACTAGTATTGCTTCAGCAATTATGTGCAATTTTTGGGCTTAAATTTACAGGAGATACGGGACAAATCATGAACCTTGTAAATACAGTTTTAACT ATTGGCGGTATTCTTGGTTTAGTAGATGGAACAACGGTTGATGTTGATACAGTCAATACGATTGAACAAACAGCAAATAAAGCTTTAAAACTTGCGAAAATAAGCAATGATACTCCTAAATCTTTAGCAGAAATGATTGACAAGGACG
[0140] It is known from common technical knowledge that the present invention can be implemented by other embodiments that do not deviate from its spirit or essential features. Therefore, the above disclosed embodiments are only illustrative in all respects and are not exclusive. All changes within the scope of the present invention or within the scope equivalent to the present invention are included in the present invention.
Claims
1. A specific primer pair, characterized in that: The primer sequences of the primer pair are shown as SEQ ID NO.1 and SEQ ID NO.2 respectively.
2. A kit, characterized in that: The kit contains the specific primer pair according to claim 1.
3. A method for detecting Lactobacillus salivarius with a deposit number of CCTCC NO: M2023348 for non-diagnostic purposes, comprising using the specific primer pair described in claim 1 or the kit described in claim 2 to detect the genomic template in the sample to be tested.
4. Use of the specific primer pair according to claim 1 or the kit according to claim 2 in preparing a preparation for evaluating the therapeutic effect of a probiotic, wherein the probiotic is Lactobacillus salivarius with a microbial preservation number of CCTCC NO: M2023348.
5. Use of the specific primer pair according to claim 1 or the kit according to claim 2 in preparing a preparation for formulating or adjusting a treatment plan for a tumor patient.
6. The use according to claim 4, characterized in that The therapeutic effect is the effect of treating diarrhea caused by chemotherapy drugs or diarrhea caused by any one or more of Pseudomonas aeruginosa, Shigella, Escherichia coli, Salmonella paratyphi B, Yersinia enterocolitica, Staphylococcus aureus, Vibrio parahaemolyticus, and Clostridium difficile.
7. The use according to claim 4 or 5, characterized in that The method for realizing the use is: qualitatively or quantitatively detecting Lactobacillus salivarius with a microbial preservation number of CCTCC NO: M2023348 in the intestinal contents or feces of the subject.
8. The use according to claim 6, characterized in that The chemotherapy drug is selected from 5-fluorouracil, capecitabine, gemcitabine, methotrexate, pemetrexed, cytarabine, doxorubicin, epirubicin, dactinomycin D, doxorubicin, daunorubicin, paclitaxel, docetaxel, albumin paclitaxel, cisplatin, carboplatin, nedaplatin, oxaliplatin, lobaplatin, cyclophosphamide, nitrogen mustard, carmustine, camptothecin, hydroxycamptothecin, topotecan, irinotecan and their derivatives.
